Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma

NCT04323956 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Ann Arbor Stage II Diffuse Large B-Cell Lymphoma
Ann Arbor Stage II Follicular Lymphoma
Ann Arbor Stage II Marginal Zone Lymphoma
Ann Arbor Stage III Diffuse Large B-Cell Lymphoma
Ann Arbor Stage III Follicular Lymphoma
Ann Arbor Stage III Marginal Zone Lymphoma
Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma
Ann Arbor Stage IV Follicular Lymphoma
Ann Arbor Stage IV Marginal Zone Lymphoma
Diffuse Large B-Cell Lymphoma
High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements
High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements
Indolent Non-Hodgkin Lymphoma

Interventions

DRUG: Cyclophosphamide
DRUG: Doxorubicin Hydrochloride
DRUG: Parsaclisib
BIOLOGICAL: Pegfilgrastim
DRUG: Polatuzumab Vedotin
DRUG: Prednisone
BIOLOGICAL: Rituximab
DRUG: Vincristine Sulfate

Sponsor

Mayo Clinic